1Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, Harry D, Moore K. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet, 1999, 353:294～295.
2Van Roey G, Moore K. The hepatorenal syndrome. Pediatr Nephrol, 1996,10:100～107.
3Moore K. The hepatorenal syndrome. Clin Sci (Colch), 1997,92:433-443.
4Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis, 1994,14:71～81.
5Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H,Scholmerich J. Definition and diagnostic of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology,1996,23:164～176.
6Epstein M. Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol, 1994,4:1735～1753.
7Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol, 1999,10:1833-1839.
8Maroto A, Gines P, Arroyo V, Gines A, Salo J,Claria J, Jimenez W, Btu C, Rivera F, Rodes J.Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology,1993,17:788～793.
9Guevara M, Bru C, Gines P, Fernandez-Esparrach G, Sort P, Bataller R, Jimenez W, Arroyo V, Rodes J. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology,1998,28:39～44.
10Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med, 1998,339:533～541.
同被引文献4
1GENTILIM P, VIXXUTrI F. Update on ascite and hepatorenal syndrome[J]. Dig Liver Dis,2002,34(8) :592-605.
2SOLANKI P, CHAWLA A. Benificial effect of terlipression in hepatorenal syndrome: a prospective, randomized placebo controlled clinical trial [ J ]. Gastroentrol Hepatol,2003,18 (2): 152 -156.
